NCT03967691View on ClinicalTrials.gov

IL-6 Regulation of Substrate Metabolism and Influence of Obesity

NACompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 12, 2019

Primary Completion Date

April 3, 2020

Study Completion Date

April 3, 2020

Conditions
ObesityHealthy
Interventions
DRUG

Tocilizumab infusion

Tocilizumab (8mg/kg body weight diluted to 100 ml NaCl 0.9%) will be infused over 1 hour

DRUG

Saline 0.9%

100 ml NaCl 0.9% will be infused over 1 hour

Trial Locations (1)

2100

Rigshospitalet, Centre of Inflammation and Metabolism (CIM) Centre for Physical Activity Research (CFAS), Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT03967691 - IL-6 Regulation of Substrate Metabolism and Influence of Obesity | Biotech Hunter | Biotech Hunter